The charts on this page feature a breakdown of the total annual pay for the top executives at OLEMA PHARMACEUTICALS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. OLEMA PHARMACEUTICALS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. OLEMA PHARMACEUTICALS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Sean Bohen
President and Chief Executive Officer
Total Cash $987,700 Equity $2,324,250 Other $11,600 Total Compensation $3,323,550
Kinney Horn
Chief Business Officer
Total Cash $576,700 Equity $1,239,600 Other $11,600 Total Compensation $1,827,900
Shane Kovacs
Chief Operating and Financial Officer
Total Cash $690,900 Equity $0 Other $184,650 Total Compensation $875,550
For its 2021 fiscal year, OLEMA PHARMACEUTICALS INC, listed the following board members on its annual proxy statement to the SEC.
Andrew Rappaport Total Cash $431,030
Cynthia Butitta Total Cash $439,030
Frank McCormick, Ph.D., F.R.S., D.Sc. (Hon) Total Cash $11,813
Gorjan Hrustanovic, Ph.D. Total Cash $427,030
Graham Walmsley, M.D., Ph.D. Total Cash $430,030
Ian Clark Total Cash $459,030
Sandra Horning, M.D. Total Cash $417,030
Yi Larson Total Cash $972,266

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.